BCL2 and small cell lung carcinoma: In preclinical models of SCLC, combined inhibition of BCL-2 or BCL-XL and MCL1 showed synergistic activity (106, 107), but BCL-2 inhibition failed to improve the clinical efficacy of standard chemotherapy (108, 109).